COMMUNIQUÉS West-GlobeNewswire

L’édition 2024 du congrès FAAM-EUROBAT s’achève sur des avancées révolutionnaires en matière de recherche sur les allergies alimentaires et l’anaphylaxie
13/12/2024
ATHÈNES, Grèce, 13 déc. 2024 (GLOBE NEWSWIRE) -- L’édition 2024 du congrès FAAM-EUROBAT , organisé du 21 au 23 novembre à l’InterContinental Athenaeum d’Athènes, a rassemblé 550 participants en provenance de plus de 25 [...]
CannExpo 2025: Igniting the Cannabis Lifestyle in Toronto
13/12/2024
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Get ready to elevate your cannabis experience at CannExpo 2025, Toronto's Cannabis Lifestyle Show, blazing into the Queen Elizabeth Building at Exhibition Place on [...]
Protest as MPPs come to Stratford on pre-budget tour: Local citizens angry at Ford government for underfunding, privatizing & destroying our public health care plan to make their voices heard
13/12/2024
Attn: Assignment Editor STRATFORD, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) -- As the government travels to Stratford to hold Pre-Budget Hearings, concerned citizens from Stratford and area will gather to send a message [...]
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering
13/12/2024
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
13/12/2024
Incumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on [...]
Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2)
13/12/2024
DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. FDA in [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
13/12/2024
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List
13/12/2024
CLEVELAND, Dec. 13, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics has been named to the Crain’s Cleveland Business Fast 50, placing first on the list of rapidly growing, privately held companies ranked by revenue growth [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
13/12/2024
Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change Incumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has [...]
PharmAla Announces Private Placement
13/12/2024
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Amarin Appoints Peter Fishman Chief Financial Officer
13/12/2024
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today [...]
QHSLab (OTCQB:USAQ) and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology
13/12/2024
NSF Recognition: A Testament to Innovation Driving Strategic Growth and Shareholder Value WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ) , a leading provider of digital [...]
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13/12/2024
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple [...]
Sienna Announces December Dividend
13/12/2024
MARKHAM, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
13/12/2024
Same-day dosing results comparable to next day dosing schedules LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with [...]
iTeos Therapeutics présente les données intermédiaires de l’essai clinique A2A-005, ainsi que les données translationnelles et précliniques relatives à l’inupadénant lors du congrès d’immuno-oncologie de l’ESMO
13/12/2024
- L’essai de phase 2 A2A-005 portant sur l’inupadénant + carboplatine/pémétrexed a démontré un taux de réponse globale (TRG) de 63,9 % et une SSP médiane de 7,7 mois pour tous les patients évaluables sur l’ensemble des [...]
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
13/12/2024
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria [...]
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
13/12/2024
INX-315 was safe and well tolerated in monotherapy dose escalation INX-315 monotherapy demonstrated antitumor activity in heavily pretreated patients with ER+/HER2- breast cancer and CCNE1-amplified ovarian cancer [...]

Pages